ArticleAnnals of hematology2026
Red blood cell alloimmunization in transfusion-dependent β-thalassemia major patients in Eastern Iran.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with thalassemia major require regular blood transfusions, which cause complications such as iron overload, increased risk of blood-borne diseases, and production of alloantibodies against donor blood cells. This study aimed to investigate the prevalence and types of alloantibodies in patients with transfusion-dependent thalassemia. This cross-sectional study was conducted on 74 transfusion-dependent thalassemia patients in southern Khorasan Province, Iran. The patients’ ABO and Rh blood groups phenotyping was determined. Serum samples from all patients underwent initial antibody screening, followed by antibody identification in samples that tested positive. Demographic information of patients was extracted from their electronic records. This study included 37 males and 37 females, 50% each, aged 1–37 years old. Antibody screening was positive in 7 patients (9.5%). 16 alloantibodies were identified. The most prevalent alloantibodies were anti-K (43.75%) and anti-E (43.75%), followed by anti-C (12.5%). Within the ABO system, blood group O was the most frequent phenotype (39.2%), while in the Rh system, antigens C and E were the most common, present in 94.6% of participants. Statistical analysis revealed no significant association between alloimmunization and demographic data such as age, sex, blood group, hemoglobin levels, number of blood units transfused and splenic status. Our results show that alloimmunization is still a chronic problem in our transfusion-dependent thalassemia group, despite the recognized benefits of antigen-matched transfusions. These results reinforce the necessity of using regionally specific approaches to improve transfusion safety, such as expanded donor phenotyping and regular antibody screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.